STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity
How obesity medications may become the next big battleground over access to medicines in lower-income countries.
Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, sold as Wegovy by Novo Nordisk for obesity, began to appear in some countries and will soon arrive in others. Meanwhile, pharmaceutical companies are working to create newer GLP-1 medications that promise to be more effective, have fewer side effects, and are simpler to administer.
While these advances could help more people lose weight, they may also spark a new controversy over access to medicines in lower-income nations, according to Ken Shadlen, a professor at the London School of Economics who studies pharmaceutical and health regulations. Our conversation with him follows.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.